BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer 2020;8:e000734. [PMID: 32661116 DOI: 10.1136/jitc-2020-000734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Noori S, Verkleij CPM, Zajec M, Langerhorst P, Bosman PWC, de Rijke YB, Zweegman S, VanDuijn M, Luider T, van de Donk NWCJ, Jacobs JFM. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. Clin Chem Lab Med 2021. [PMID: 34392637 DOI: 10.1515/cclm-2021-0399] [Reference Citation Analysis]
2 Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, Wheeler ML, Bezman N, Wang F, Strop P, Leif Bergsagel P, Chesi M. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov 2021;2:354-69. [PMID: 34258584 DOI: 10.1158/2643-3230.bcd-21-0038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Radocha J, van de Donk NWCJ, Weisel K. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. Cancers (Basel) 2021;13:1571. [PMID: 33805481 DOI: 10.3390/cancers13071571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Wahab A, Rafae A, Mushtaq K, Masood A, Ehsan H, Khakwani M, Khan A. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma. Front Oncol 2021;11:678634. [PMID: 34046363 DOI: 10.3389/fonc.2021.678634] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang F, Luo Y, Zhang L, Younis M, Yuan L. The LncRNA RP11-301G19.1/miR-582-5p/HMGB2 axis modulates the proliferation and apoptosis of multiple myeloma cancer cells via the PI3K/AKT signalling pathway. Cancer Gene Ther 2021. [PMID: 33707625 DOI: 10.1038/s41417-021-00309-5] [Reference Citation Analysis]
6 Isola I, Brasó-Maristany F, Moreno DF, Mena MP, Oliver-Calders A, Paré L, Rodríguez-Lobato LG, Martin-Antonio B, Cibeira MT, Bladé J, Rosiñol L, Prat A, Lozano E, Fernández de Larrea C. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Front Immunol 2021;12:792609. [PMID: 34880879 DOI: 10.3389/fimmu.2021.792609] [Reference Citation Analysis]
7 Banerjee R, Lo M, Martin TG 3rd. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma. Future Oncol 2021. [PMID: 34553603 DOI: 10.2217/fon-2021-0778] [Reference Citation Analysis]
8 Yang Y, Liu Z, Wang H, Zhang G. HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma. Front Oncol 2021;11:670673. [PMID: 34178656 DOI: 10.3389/fonc.2021.670673] [Reference Citation Analysis]
9 Rodriguez C. An Overview of Organoid and 3-Dimensional Models in Multiple Myeloma. Cancer J 2021;27:239-46. [PMID: 34549913 DOI: 10.1097/PPO.0000000000000526] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]